Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company that develops treatments for rare and ultra-rare diseases. Its lobbying filings show it advocates on health and government issues, especially monitoring Food and Drug Administration user fee rules and seeking reauthorization of priority review vouchers, and supporting legislation on newborn screening and diseases like Duchenne muscular dystrophy. It has spent about $100,000 and used the Alpine Group Partners, LLC.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
ERIN MENDELSOHN
The latest disclosures for this client.
ALPINE GROUP PARTNERS, LLC.
Q1ALPINE GROUP PARTNERS, LLC.
Q2The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
ALPINE GROUP PARTNERS, LLC.
KEENAN AUSTIN REED
ALPINE GROUP PARTNERS, LLC.
SHAYNE WOODS
ALPINE GROUP PARTNERS, LLC.
ALPINE GROUP PARTNERS, LLC.
RR